Vor Biopharma Inc. (NYSE:VOR) Receives $10.92 Average Target Price from Brokerages

Vor Biopharma Inc. (NYSE:VOR) has earned a consensus rating of “Buy” from the six ratings firms that are presently covering the stock, Marketbeat reports. Six research analysts have rated the stock with a buy rating. The average 1 year target price among brokers that have covered the stock in the last year is $10.92.

A number of equities research analysts have recently issued reports on the stock. JMP Securities reissued a “market outperform” rating and issued a $12.00 price target on shares of Vor Biopharma in a report on Friday, September 6th. HC Wainwright restated a “buy” rating and issued a $17.50 price objective on shares of Vor Biopharma in a research report on Friday, September 6th. Finally, Barclays decreased their price objective on shares of Vor Biopharma from $10.00 to $3.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 14th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Hsbc Holdings PLC grew its position in Vor Biopharma by 177.0% during the second quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock valued at $51,000 after acquiring an additional 31,333 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in Vor Biopharma during the second quarter valued at approximately $53,000. Acadian Asset Management LLC bought a new position in shares of Vor Biopharma in the first quarter worth approximately $126,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Vor Biopharma in the second quarter worth approximately $63,000. Finally, Rosalind Advisors Inc. bought a new position in shares of Vor Biopharma in the third quarter worth approximately $54,000. 97.29% of the stock is currently owned by institutional investors.

Vor Biopharma Trading Up 7.9 %

Shares of Vor Biopharma stock opened at $0.80 on Monday. Vor Biopharma has a 12-month low of $0.63 and a 12-month high of $3.14. The company has a market cap of $54.61 million, a price-to-earnings ratio of -0.46 and a beta of -0.35. The company’s 50-day moving average price is $0.81 and its 200-day moving average price is $1.11.

Vor Biopharma (NYSE:VOR) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.41). On average, sell-side analysts predict that Vor Biopharma will post -1.51 earnings per share for the current year.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.